The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST).
 
Solange Peters
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ecancer (Inst); Ecancer (Inst); Illumina (Inst); Imedex (Inst); medscape (Inst); MSD (Inst); Novartis (Inst); PER (Inst); Pfizer (Inst); Prime Oncology (Inst); Research to Practice (Inst); RMEI Medical Education (Inst); Roche (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Biocartis (Inst); Bioinvent (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Illumina (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Phosplatin Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Biodesix (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Illumina (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche; Sanofi
(OPTIONAL) Uncompensated Relationships - Annals of Oncology (I); ESMO; European Thoracic Oncology Platform (ETOP); Journal of Thoracic Oncology
 
Shirish M. Gadgeel
Honoraria - Merck
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; Daichii-Sanyko; Genentech/Roche; Janssen Oncology; Lilly; Mirati Therapeutics; Novartis; Pfizer; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); Daichii Sanyko (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Erasca, Inc (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); I-Mab (Inst); Incyte (Inst); InventisBio (Inst); Janssen Oncology (Inst); Merck; Merck (Inst); Mirati Therapeutics (Inst); Nektar (Inst); Nektar (Inst); Numab (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); Ymabs Therapeutics Inc (Inst)
Travel, Accommodations, Expenses - Merck
Other Relationship - AstraZeneca
 
Tony S. K. Mok
Employment - The Chinese University of Hong Kong
Leadership - ACT Genomics-Sanomics Group; AstraZeneca; Aurora Tele-Oncology Platform; HUTCHMED; Lunit
Stock and Other Ownership Interests - ACT Genomics-Sanomics Group; Aurora Tele-Oncology Platform; HUTCHMED
Honoraria - Abbvie; ACEA Pharmaceutical Research; Alpha Biopharma; Amgen; Amoy Diagnostics; AstraZeneca; BeiGene; Berry Oncology; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; C4 Therapeutics; CStone Pharmaceuticals; Curio Science; D3; Daiichi Sankyo/UCB Japan; Eisai; Fishawack Facilitate; Gilead Sciences; Gritstone Bio; Guardant Health; InMed; Lilly; Lucence; Medscape; Merck Sharp & Dohme; Novartis; Origimed; PeerVoice; Permanyer Publications; Pfizer; Physicans' Education Resource; Prime Oncology; Research to Practice; Roche; Sanofi Aventis GmbH; Shanghai BeBirds Translation & Consulting; Suzhou Liangyihui Network Technology; Taiho Pharmaceutical; Takeda; touchIME
Consulting or Advisory Role - Abbvie; ACEA Pharmaceutical Research; Alpha Biopharma; Amgen; Amoy Diagnostics; AstraZeneca; BeiGene; Berry Oncology; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; C4 Therapeutics; CStone Pharmaceuticals; Curio Science; D3; Daiichi Sankyo/UCB Japan; Eisai; Fishawack Facilitate; G1 Therapeutics; geneDecode; Gilead Sciences; Gritstone Bio; Guardant Health; Hengrui Therapeutics; Ignyta; Incyte; Inivata; IQvia; Janssen; Lilly; Loxo; Lunit; Merck Serono; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Pfizer; Puma Biotechnology; Qiming Development (HK) Ltd.; Roche; SFJ Pharmaceuticals Group; Takeda; Vertex; Yuhan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Takeda (Inst); Xcovery (Inst)
 
Ernest Nadal
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche; Sanofi; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Merck Serono (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche
 
Saadettin Kilickap
No Relationships to Disclose
 
Maurice Perol
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daïchi Sankyo; GlaxoSmithKline; Gritstone Bio; Janssen Oncology; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Merck Sharp & Dohme; Pfizer; Roche; Takeda
 
Jacques Cadranel
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer; Roche; Takeda
Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst)
 
Shunichi Sugawara
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Kirin; Lilly; Merck; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; TOWA PHARMACEUTICAL; Yakult Honsha
 
Chao-Hua Chiu
Honoraria - Amgen; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Lilly; Merck KGaA; MSD; Novartis; Roche
Speakers' Bureau - Amgen; MSD
 
Mor Moskovitz
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - MSD; Takeda
Research Funding - AstraZeneca (Inst)
 
Chong-Jen Yu
No Relationships to Disclose
 
Tomohiro Tanaka
Employment - Chugai Pharma
 
Rhea Nersesian
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Sarah M. Shagan
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Patents, Royalties, Other Intellectual Property - Patent author; application filed
 
Margaret Maclennan
Employment - Syneos Health
Stock and Other Ownership Interests - Alere
 
Michael Mathisen
Employment - Roche/Genentech
 
Vijay N S Bhagawati Prasad
Employment - Roche Pharma AG
Stock and Other Ownership Interests - Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech
 
Venice Rosalie Archer
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech
 
Rafal Dziadziuszko
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Novartis; PFIZER; Roche/Genentech; Seagen; Takeda
Consulting or Advisory Role - Karyopharm Therapeutics; Regeneron
Travel, Accommodations, Expenses - AstraZeneca; Roche